Cardiovascular disease risk markers Circulatory System Cardiovascular disease
Conditions
Interventions
The dietary interventions proposed for this project are designed to compare three diets, each of which are practical and realistic for individuals to achieve. Each dietary intervention will be of 12 w
Sponsors
University of Aberdeen (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 40 - 65 years 2. Body mass index (BMI) between 25 and 35 kg/m^2 3. Recruited from the surrounding community of Aberdeen 4. Sedentary or moderately active (less than two aerobic session per week) 5. Present signs of metabolic syndrome, e.g., if he/she has three or more of the following conditions: 5.1. Fasting plasma glucose (greater than 6.1 mm/L) 5.2. Triacylglycerol (TAG) level (greater than 1.7 mmol/L) 5.3. Low high density lipoprotein (HDL) cholesterol (less than 1.04 mmol/L for men, less than 1.29 mmol/L for women) 5.4. Hypertension (greater than 130/85 mmHg) 5.5. Central obesity (waist circumference greater than 102 cm for men, greater than 88 cm for women) 5.6. Moderate hypercholesterolaemia
Exclusion criteria
Exclusion criteria: 1. Cardiovascular disease (CVD) 2. Diabetes 3. Asthma 4. Systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 99 mmHg 5. Thyroid gland disorders or eating disorders 6. Regularly taking medication or supplements known to affect any dependant variable measured 7. High habitual intake of tomato-based food (greater than 5 servings per week) 8. Regularly taking nutritional supplements such as antioxidants or fish oil
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum total and low density lipoprotein (LDL) cholesterol and intercellular adhesion molecule 1 (ICAM-1) concentrations. All outcomes are measured four times during the study: prior run-in periods, at baseline (after run-in period), after 6 and 12 weeks intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin sensitivity as well as vascular function and inflammation markers (vascular tonicity by pulse-wave velocity, interleukin-6 [IL-6] and high sensitivity C-reactive protein [hsCRP]). All outcomes are measured four times during the study: prior run-in periods, at baseline (after run-in period), after 6 and 12 weeks intervention. | — |
Countries
Scotland, United Kingdom
Outcome results
None listed